Garcia-Arieta [7] described two unpublished bioequivalence studies where sorbitol (7 mg and 50 mg sorbitol doses) apparently led to bioequivalence failure of risperidone solution formulations, due to the lower bound of the Cmax confidence interval falling outside the acceptable range (90% CIs 77.0–99.2 and 76.20–102.82, respectively).